<DOC>
	<DOCNO>NCT02894307</DOCNO>
	<brief_summary>Anticoagulant treatment reduces incidence death cardioembolic event patient atrial ﬁbrillation prosthetic heart valve incidence death recurrence patient VTE . Warfarin similar vitamin K antagonist ( VKA ) standard therapy patient metallic valve , bioprosthesis atrial fibrillation ( AF ) . The Dabigatran versus Warfarin Patients Mechanical Heart Valves ( RE-ALIGN ) trial compare dabigatran etexilate warfarin randomize control study patient mechanical valve prosthesis , terminate prematurely excess thromboembolic bleed event among patient dabigatran group . To date , novel oral anticoagulant ( NOACs ) show safe effective patient mechanical valve .</brief_summary>
	<brief_title>Rivaroxaban Apixaban Mechanical Valves : RAMV</brief_title>
	<detailed_description>Anticoagulant treatment reduces incidence death cardioembolic event patient atrial ﬁbrillation prosthetic heart valve incidence death recurrence patient VTE . Warfarin similar vitamin K antagonist ( VKA ) standard therapy patient metallic valve , bioprosthesis atrial fibrillation ( AF ) . Warfarin work bind vitamin K epoxide reductase inhibit vitamin K-dependent coagulation factor II , VII , IX , X . For extensive use , warfarin many clinical shortcoming , include variable pharmacokinetic pharmacodynamics property , narrow therapeutic index range , numerous interaction certain food drug . All factor contribute need frequent coagulation laboratory monitoring dosage adjustment . Even appropriate use therapy , incidence thromboembolic event still substantial : 1-4 % per year . Furthermore , bleed risk significant , range 2 % 9 % per year . The VKA 's narrow therapeutic index complex pharmacology , e.g . long pharmacologic inertia common interaction drug . These feature make management drug challenge physician patient . The Dabigatran versus Warfarin Patients Mechanical Heart Valves ( RE-ALIGN ) trial compare dabigatran etexilate warfarin randomize control study patient mechanical valve prosthesis , terminate prematurely excess thromboembolic bleed event among patient dabigatran group . Most thromboembolic event among patient dabigatran group occur population A ( patient start study drug within 7 day valve surgery ) , few occur population B ( patient undergone valve implantation 3 month randomization ) . Besides , stroke , death major bleeding occur population A . In study , rivaroxaban use patient mechanical valve unstable INR design .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Age 18 64 year entry ; Patients mitral and/or aorthic mechanical valve least 3 month postoperatively ; Brain compute tomography scan without hemorrhage finding acute cerebral infarction last 2 day screen ; Exclusion atrial thrombus valve prosthesis thrombosis transesophageal echocardiograph last 2 day screen ; Written , informed consent ; Previous hemorrhagic stroke ; Ischemic stroke last 6 month ; Renal impairment ( creatinine clearance rate &lt; 50 ml/min ) ; Active liver disease ( etiology ) ; Concomitant use antiplatelet ( aspirin , clopidogrel , prasugrel , ticagrelor , ticlopidine , etc ) ; Increased risk bleeding ( congenital acquire ) ; Uncontrolled hypertension ; Gastrointestinal hemorrhage within past year ; Anemia ( hemoglobin level &lt; 10 g/dL ) thrombocytopenia ( platelet count &lt; 100 × 109/L ) ; Active infective endocarditis ; Pregnant lactate woman ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEchanical valve</keyword>
	<keyword>Rivaroxaban</keyword>
</DOC>